## Pharma OICE

THE FORUM FOR THE INDUSTRY EXECUTIVE

Volume 4 • Number 11

PUBLISHER Lisa Banket
EDITOR Taren Grom
CREATIVE DIRECTOR Marah Walsh

**MANAGING EDITOR** 

Denise Myshko

**ASSOCIATE EDITOR** 

Elisabeth Pena

**CONTRIBUTING EDITOR** 

Kim Ribbink

**DESIGN ASSOCIATES** 

Jane Baxter Cathy Liszewski

**NATIONAL ACCOUNT MANAGER** 

Melissa Drozdoff

**SALES ASSISTANT** 

Jayme Hudson

Copyright 2004 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Four, Number Eleven

**PharmaVOICE** is published 12 times per year by Pharma-Linx LLC, P.O. Box 327, Titusville, NJ 08560. Application to mail at Periodicals Postage Rates is pending at Titusville, NJ 08560 and additional mailing offices.

**Postmaster:** Send address changes to PharmaVOICE, P.O. Box 327, Titusville, NJ 08560.

## PharmaVOICECoverage and Distribution:

Domestic subscriptions are available at \$190 for one year (12 issues). Foreign subscriptions: 12 issues US\$360. Contact PharmaVOICE at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVOICE is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVOICE retains all rights on material published in PharmaVOICE for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVOICE, P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your change to 609.730.0197. E-mail: mwalsh@pharmavoice.com.

**IMPORTANT NOTICE**: The post office will not forward copies of this magazine. PharmaVOICE is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVOICE: To advertise in Pharma-VOICEplease contact our Advertising Department at P.O.Box 327, Titusville, NJ 08560, or telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com.

## Letters

Send your letters to feedback@pharmavoice.com. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC. ccording to ex ecutives across all industry sect ors, the RFP process is here to stay. B ut business is far from usual as pharma companies continue to implement sourcing management structures to leverage volume purchases to drive savings and ser vice enhancements, as well as e-t echnologies that allow for the process to be completed over the Internet.

As the pharmaceutical industry continues to grapple with pressures on its top line, companies are searching for ways to boost their bottom line by reducing costs across all of their outsourced needs. As such the provider selection process is undergoing a transformation.

"Different companies are going about this in different ways," says Matt Giegerich, president and CEO of CommonHealth. "Some are using outside consultants and intense procurement efficiency models and departments. Others are looking at consolidating their supplier rosters on every front, not just marketing services. All of this is in a quest to prop up the bottom line by wringing out any unnecessary costs. The RFP process used to be fairly simple; the primary decision maker within the marketing department was responsible for awarding new business and shepherding existing relationships. The assessment of quality emanated from a single point person or a single team. Now, with contracting and procurement departments in the mix, this is a shared responsibility."

Pharmaceutical company executives are not wholly unsympathetic to the demands facing their provider partners, but maintain that their procurement departments are driving better business decisions because the process is unbiased and based on data.

"RFPs will continue to be used as a way of competing to gain the business," says Mike Thyen, manager of global sourcing at Eli Lilly. "The internal team can review more data to make the best decision, as well as evaluate multiple suppliers. There are more and more electronic-based tools that allow this process to be efficient. There also is going to be more diligence on the cost elements since companies will have data that they have collected from past RFPs. Companies are nat-



There has been an increase in use of technology, with more sponsors creating Web-based portals for posting RFPs and receiving proposals; requests for RFPs to prequalify suppliers before participating in the full-blown bid process; and an increase in the number of preferred provider relationships, which limits how many companies they will do business with.

urally going to look at how the proposal has changed versus historical data that they received from a company or in an area of spend. The best relationships that we have with suppliers and internal clients are those that have embraced the RFP process and the procurement organization."

According to Ara Kebabjian, global sourcing, marketing services, at Novartis Pharmaceuticals Corp., whether a company is sourcing information technology such as laptops or procuring marketing services, a consolidation of spend to a fewer number of more strategic suppliers can lead to benefits for a company.

Additionally, suppliers are being asked to provide more detailed information than ever before as part of the process, whether they are competing in the marketing, clinical, or IT arenas.

"Some of the more significant changes we've encountered in the RFP process include: sponsor requests for strategic guidance on study design; recommendations on innovative and creative study design and operational strategies during the RFP stage; and sponsor supplied pricing templates so that bids can be compared on an apples-to-apples basis," says Simon S. Higginbotham, VP and chief marketing officer at Kendle International Inc.

Taren Grom Editor

www.pharmavoice.com

PharmaVOICE November 2004